



BOSTIK CEMENTONE CONCENTRATED MORTAR PLASTICISER

Revision date 21-Aug-2026

Supersedes date 15-Aug-2026

European Union

Registration, Evaluation, Authorisation, and Restriction of Chemicals (REACH) Regulation (EC 1907/2006)

SVHC: Substances of Very High Concern for Authorisation:

This product does not contain candidate substances of very high concern at a concentration $\geq 0.1\%$ (Regulation (EC) No. 1907/2006 (REACH), Article 59)

Effective date 04/02/2026 (DD/MM/YYYY)

This document reflects all substances present on the Candidate list of substances for authorisation as per the date of issue of this document. Should the SVHC status of one of our products change, Bostik will comply with their communication responsibility according to the REACH Regulation by updating SDS which is distributed to customers who have purchased within previous 365 days.

Bostik is fully aware of its obligations towards the registration of concerned Articles in SCIP Database (Substances of Concern in articles as such or in complex objects (Products)) established under the Waste Framework Directive (WFD). This product is not in scope of SCIP requirements as it is considered chemical product and not article therefore there will be no obligations under SCIP based on the above.

PPWR – Packaging and Packaging Waste Regulation - CHEMICAL PRODUCT

Regulation (EU) 2025/40 (PPWR) is partially repealing Directive 94/62/EC and some articles apply from August 12, 2026 (Art. 70 and 71).

o Lead, cadmium, mercury and hexavalent chromium themselves and resulting from substances. Sum of their concentrations shall not exceed 100 mg/kg.

o Per- and polyfluorinated alkyl substances PFAS (specific PFCAs (C9-C20), Perfluorooctanoic acid (PFOA, CAS 335-67-1), Perfluorooctane Sulfonate (PFOS) and other fluorinated substances).

Additionally, to the best of our knowledge and based on the information given to us by our raw material suppliers, these substances are not present in the raw materials we buy.

Please note we are actively aligning our portfolio with PPWR requirements and will ensure that our chemical products we supply meet the applicable provisions by 12 August 2026, to the extent these can be implemented based on current technical and regulatory information.

This statement only concerns chemical products sold by Bostik (packaging of our products will be the subject of a dedicated statement).

Given this declaration, we do not analyze our products and/or the related raw materials for these substances/compounds.

Persistent Organic Pollutants (POP) – EU Regulation

Based on the information from our suppliers and the final product composition, we do not knowingly add any materials classified as a Persistent Organic Pollutant (POP), as defined by Stockholm Convention and set out in the EU Regulation 2019/1021 and amendments in force, during the production of this product, nor do our suppliers report the inclusion of these materials in their products

Regulation (EU) 2019/1148 of 20 June 2019 on the marketing and use of explosives precursors

Not applicable.



Revision date: 21-Aug-2026

BOSTIK CEMENTONE CONCENTRATED MORTAR PLASTICISER

Regulations on drug precursors (EC) No 111/2005 (export) and 273/2004 (internal trade)

This product does not contain any substance(s) on the Drug Precursors list.

Directive 2011/65/EU (EU RoHS 2), as amended by the Delegated Directive (EU) 2015/863 (EU RoHS 3)

This product does not contain Lead, Cadmium, Mercury, Hexavalent chromium, Polybrominated biphenyls (PBB), Polybrominated diphenyl ethers (PBDE), Bis(2-Ethylhexyl) phthalate (DEHP), Benzyl butyl phthalate (BBP), Dibutyl phthalate (DBP) and Diisobutyl phthalate (DIBP) above the regulated limit mentioned in this regulation. This document is based on the information given to us by our own suppliers at the date of this document.

Export and import of hazardous chemicals (Regulation (EC) No 649/2012)

This product does not contain substances which are regulated pursuant to Regulation (EC) No. 649/2012 of the European parliament and of the council concerning the export and import of dangerous chemicals above the level that triggers a labeling obligation under Regulation (EC) No 1272/2008. Therefore this product is not subject to prior informed consent notification.

2017/821/EU Conflict Minerals

Regulation (EU) 2017/821 of 17 May 2017 concerning minerals originating from conflict-affected and high-risk areas entered into full force on 1st January 2021.

Bostik certifies that we do not intentionally add minerals (tin, tantalum, tungsten, gold, or their derivatives) coming from these areas for the manufacturing of this product.

Additionally, to the best of our knowledge and based on the information given to us by our raw material suppliers, these minerals or their derivatives are not present in the raw materials we buy.

Substance related information

Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS)

Bostik hereby certifies that, to the best of our knowledge, we do not intentionally add any Per- and polyfluorinated alkyl substances PFAS (specific PFCAs (C9-C20), Perfluorooctanoic acid (PFOA, CAS 335-67-1), Perfluorooctane Sulfonate (PFOS) and other fluorinated substances) for the manufacturing of this product.

United States of America

California Proposition 65

Substances as defined in Proposition 65 of the California Safe Drinking Water and Toxic Enforcement Act of 1986 and its amendments.

Effective date 31/07/2026 (DD/MM/YYYY)

This product contains one or more of the substances listed on Proposition 65 at or above 0.0001 wt. %.

Chemical name	California Proposition 65
Ethylene oxide - 75-21-8	Carcinogen Developmental Female Reproductive Male Reproductive
1,4-Dioxane - 123-91-1	Carcinogen



Revision date: 21-Aug-2026

BOSTIK CEMENTONE CONCENTRATED MORTAR PLASTICISER

EPA TSCA Section 6(h) (Persistent, Bioaccumulative, and Toxic (PBT) Chemicals)

Based on the information from our suppliers and the final product composition, this product is screened for Decabromodiphenyl ether (DecaBDE) (CAS # 1163-19-5), Phenol, isopropylated phosphate (3:1) (PIP (3:1)) (CAS # 68937-41-7), 2,4,6-Tris(tert-butyl)phenol (2,4,6-TTBP) (CAS # 732-26-3), Hexachlorobutadiene (HCBD) (CAS # 87-68-3), or Pentachlorothiophenol (PCTP) (CAS # 133-49-3)

EPA TSCA Section 6(h) (Persistent, Bioaccumulative, and Toxic (PBT) Chemicals)

Not present

Model Toxics in Packaging Legislation - CONEG

Heavy metal compounds (cadmium, chromium, mercury and lead) are not known or expected to be present in the above-mentioned product ≥ 100 ppm. Therefore, there is no objection to use this product in the manufacture of packaging materials intended to be covered by CONEG standard. This document is based on the information given to us by our own suppliers at the date of this document.

Conflict Minerals Disclosure

The Dodd-Frank Wall Street Reform and Consumer Protection Act of 2012, Section 1502, allows the Securities and Exchange Commission (SEC) to impose reporting requirements upon U.S. and certain foreign manufacturers if their products contain metals derived from "Conflict Minerals" – tin, tantalum, tungsten, gold, or their derivatives; or any other mineral or its derivatives determined by the U.S. Secretary of State – originating from the Democratic Republic of the Congo (DRC) and adjoining countries. As part of Arkema, Bostik is not required to make disclosures under the Act, and we do not directly purchase "conflict minerals" as identified by the SEC. Bostik is however committed to responsible sourcing and to assisting our customers in their compliance with the Act. Bostik will take proper steps to switch to conflict-free materials if at any point we become aware of non-conflict-free materials within our supply chain.

PPWR – PACKAGING AND PACKAGING WASTE REGULATION - PACKAGING OF OUR PRODUCT

Regarding Regulation (EU) 2025/40 on Packaging and Packaging Waste (PPWR), Bostik manages the compliance of the packaging covered by this statement through technical documentation and, where applicable, an EU Declaration of Conformity. Packaging suppliers support this process by providing relevant technical information and declarations. Where Bostik is the economic operator placing the packaging on the market, Bostik retains the applicable compliance documentation and makes it available to competent authorities upon request.

Based on supplier information, internal specifications, material knowledge, and internal review, we confirm the packaging of this product:

- does not contain any Substances of Very High Concern (SVHC) above the applicable REACH thresholds.
- complies with the requirements for Heavy Metals under Article 5(4) of the PPWR. To the best of our knowledge, the sum concentration of lead, cadmium, mercury, and hexavalent chromium does not exceed 100 mg/kg.

Primary packaging* of our chemical product intended to be used in Food Contact packaging

**: packaging that is directly in contact with the chemical product.*

With regard to per- and polyfluoroalkyl substances (PFAS), the PPWR introduces specific requirements for Food Contact packaging applicable from 12 August 2026 (Article 5(5)). For such applications, the regulatory thresholds are:

- o 25 ppb for any individual PFAS (targeted analysis),
- o 250 ppb for the sum of targeted PFAS,
- o 50 ppm for total PFAS, including polymeric PFAS.

Based on our current internal assessments and available supplier information, we do not expect packaging of our chemical products intended to be used in Food Contact Packaging to exceed these thresholds.

These statements are based on information provided by packaging suppliers, internal specifications, material knowledge, and Bostik's review of the relevant packaging materials and components. Our company does not routinely perform analytical testing for SVHC, Heavy Metals or PFAS. Instead, we apply a risk-based approach, relying on qualified supplier information and established supply chain controls to ensure conformity with applicable regulatory requirements.

Please note that, according to the Frequently Asked Questions (FAQ) document published by the European Commission on 26 March 2026, it is stated in Question 14 that, based on preliminary laboratory analyses conducted on selected packaging samples, only packaging materials where PFAS have been intentionally added are expected to exceed the PFAS limit values set out in Article 5(5).

This document provides general packaging-related regulatory information and does not replace technical documentation, an EU Declaration of Conformity, supplier declarations, or other legally required documentation. The information is valid as of the date of issue and may be updated if relevant requirements or supporting information change.

Regarding specific obligations for Private Label products, please consult our Regulatory Department.

Further information

Where relevant, the SDS will provide information on topics such as:

- EU - REACH (1907/2006) - Annex XIV - List of substances subject to Authorization
- EU - REACH (1907/2006) - Annex XVII - Restrictions on Certain Dangerous Substances
- Endocrine disrupting potential
- Information on long-term effects of exposure (e.g. reproductive toxicity, carcinogenicity, mutagenicity, cumulative and other chronic effects)
- Ozone-depleting substances (ODS) regulation (EC) 2024/590
- Persistent Organic Pollutants Regulation (EU) 2019/1021
- Export and import of hazardous chemicals (Regulation (EC) No 649/2012)

- Advice on safe handling**Disclaimer**

For more information, please contact your local customer service or sales representative.

Please note that we do not routinely analyze additional substances that are not listed in the Safety Data Sheet (SDS). Unless otherwise indicated, the information provided herein is based upon information from raw material suppliers, product composition and knowledge of our manufacturing process. If a questionnaire was submitted, please note that to respond to each customer in a timely and efficient manner, our company has developed and will use a standardized system to store and provide the requested information. See SDS for Health & Safety Considerations.

The regulatory statements, technical information, and all other information or recommendations contained herein are believed to be accurate as of the date hereof. All information is provided "as-is" and subject to change without notice. Since the conditions and methods of use of the product and certain information referred to herein are beyond our control, ARKEMA expressly disclaims any and all liability as to any results obtained or arising from any use of the PRODUCT or reliance on such information. As such, it is the sole responsibility of the end-user to ensure that the final product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements.

**** NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED (INCLUDING SUITABILITY FOR USE IN ANY MEDICAL DEVICE OR MEDICAL APPLICATION), IS MADE CONCERNING THE PRODUCTS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. ****

The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process.

The performance of the product, its shelf life, and application characteristics depends on many variables, and changes in these variables can impact product performance. The user should thoroughly test the suitability of the PRODUCT in advance for any intended use or application before commercialization. This is not a warranty, an agreement, or substitute for expert or professional advice. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. It is the user responsibility to require an updated version of this document.

Arkema has implemented a Medical Policy regarding the use of Arkema products in Medical Devices applications (<https://www.arkema.com/global/en/social-responsibility/innovation-and-sustainable-solutions/responsible-product-management/medical-device-policy/>). Arkema has designated Medical grades to be used for such Medical Device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in Medical Device applications that are in contact with the body and/or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in Medical Device applications that are implanted in the body and/or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices. ARKEMA does not design, manufacture and/or sell any medical devices. ARKEMA does not co-design, or offer assistance to any purchaser of its products, in their design, manufacture and/or sale of products for medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade of Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (U.S. Food and Drug Administration or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema product in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

For your internal use only. This document may not be further distributed or disclosed without prior written approval of Arkema.